» Vion Pharmaceuticals Announces Initiation Of Clinical Trial Of Cloretazine(R) (VNP40101M) In Combination With Cytarabine
VION PHARMACEUTICALS, INC. (Nasdaq: VION) announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with…